{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:26:23Z","timestamp":1793298383096,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.jacc.2009.04.053","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T15:19:38Z","timestamp":1255533578000},"page":"1609-1616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":436,"title":["The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects"],"prefix":"10.1016","volume":"54","author":[{"given":"Deepak","family":"Voora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svati H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spasojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol R.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Salisbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey S.","family":"Ginsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2009.04.053_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.04.053_bib2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","article-title":"Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease","volume":"155","author":"Ho","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2009.04.053_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2009.04.053_bib4","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy?","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2009.04.053_bib5","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data\u20142005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.053_bib6","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.053_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2005.12.005","article-title":"Statins, cardiovascular disease, and drug safety","volume":"97","author":"Gotto","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.053_bib8","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.053_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FPC.0b013e328012d0a9","article-title":"CYP2D6*4 polymorphism is associated with statin-induced muscle effects","volume":"17","author":"Frudakis","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacc.2009.04.053_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacc.2009.04.053_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacc.2009.04.053_bib12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.053_bib13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin[ast]","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.04.053_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.053_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCGENETICS.108.795013","article-title":"Pharmacogenetic predictors of statin mediated LDLc reduction and dose response","volume":"1","author":"Voora","year":"2008","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2009.04.053_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.tpj.6500035","article-title":"Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base","volume":"1","author":"Klein","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jacc.2009.04.053_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/sj.tpj.6500384","article-title":"Clinical implications of pharmacogenomics of statin treatment","volume":"6","author":"Mangravite","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jacc.2009.04.053_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jacc.2009.04.053_bib19","author":"Gauderman"},{"key":"10.1016\/j.jacc.2009.04.053_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2133\/dmpk.23.165","article-title":"Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity","volume":"23","author":"Singh","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jacc.2009.04.053_bib21","unstructured":"Zhao JJ, Rogers JD. Proceedings of the 47th ASMS Conference on Mass Spectrommetry; June 13\u201317, 1999; Dallas, TX."},{"key":"10.1016\/j.jacc.2009.04.053_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"10.1016\/j.jacc.2009.04.053_bib23","series-title":"Statistical Analysis of Epidemiologic Data","author":"Selvin","year":"1991"},{"key":"10.1016\/j.jacc.2009.04.053_bib24","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1161\/CIRCULATIONAHA.108.792986","article-title":"Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: The Framingham Offspring Study","volume":"118","author":"Frankel","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.04.053_bib25","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","volume":"97","author":"Cziraky","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.04.053_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejps.2007.12.009","article-title":"Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro","volume":"33","author":"Skottheim","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jacc.2009.04.053_bib27","unstructured":"Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998;877:i\u2013vii, 1\u201389."},{"key":"10.1016\/j.jacc.2009.04.053_bib28","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.04.053_bib29","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project","volume":"105","author":"Pfeffer","year":"2002","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109709017136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109709017136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:34:56Z","timestamp":1760013296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109709017136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0735109709017136"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2009.04.053","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2009.04.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2009.06.027","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}